intranasal RSV vaccine

The intranasal RSV vaccine is a preclinical-stage vaccine candidate developed by Xiamen YangShengTang Biotechnic for the prevention of respiratory syncytial virus (RSV) infection. Administered as an intranasal spray, the vaccine is designed to elicit both mucosal and systemic immune responses, potentially providing superior protection at the primary site of viral entry compared to traditional intramuscular vaccines. The program likely utilizes the company's core viral vector platform, which often involves a live-attenuated influenza virus vector (such as an NS1-deleted influenza virus) to deliver RSV antigens, typically the fusion (F) protein, to the respiratory tract. This approach aims to address the significant unmet need for an effective RSV vaccine in vulnerable populations, including infants and the elderly.

Other names

鼻喷RSV疫苗intranasal respiratory syncytial virus vaccine